Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-25
2005-01-25
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S256000, C514S275000, C514S299000, C514S303000, C514S314000, C514S333000, C514S336000, C514S337000, C514S338000, C514S339000, C514S357000, C544S105000, C544S333000, C544S278000, C546S277400, C546S277700, C546S281100, C546S275700, C546S284100, C546S112000, C546S118000, C546S256000, C546S122000, C546S175000, C546S297000, C546S299000
Reexamination Certificate
active
06846819
ABSTRACT:
Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
REFERENCES:
patent: 3828068 (1974-08-01), Minieri
patent: 4154943 (1979-05-01), Kuehne
patent: 4977159 (1990-12-01), Sevrin et al.
patent: 5614551 (1997-03-01), Dick et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5932743 (1999-08-01), Collini et al.
patent: 5985867 (1999-11-01), Rodgers et al.
patent: 6346391 (2002-02-01), Oethinger et al.
patent: 6372752 (2002-04-01), Staveski et al.
patent: 6451816 (2002-09-01), Biedermann et al.
patent: 6469046 (2002-10-01), Daines et al.
patent: 6503903 (2003-01-01), Miller et al.
patent: 6503908 (2003-01-01), Maw
patent: 6559172 (2003-05-01), Heerding et al.
patent: 6573272 (2003-06-01), Miller et al.
patent: WO 9857952 (1998-12-01), None
patent: 0407200 (1990-05-01), None
patent: WO 9518619 (1995-07-01), None
patent: WO 9600730 (1996-01-01), None
patent: WO 9748696 (1997-12-01), None
patent: WO 0126652 (2001-04-01), None
patent: WO 0126654 (2001-04-01), None
patent: WO 0126654 (2001-04-01), None
patent: WO 0127103 (2001-04-01), None
patent: WO 0148248 (2001-07-01), None
patent: WO 0242273 (2002-05-01), None
patent: WO 0248097 (2002-06-01), None
Stütz et al., “Synthesis and Structure-Activity Relationships of Naftifine-Related Allylamine Antimycotics,” Journal of Medicinal Chemistry, 1986, vol. 29, No. 1, 112-125.
Misztal et al., “Synthesis and Pharmacologic Properties of Pyridol Derivatives of 3-Methylaminoindole 2-Methyltryptamine and Isotryptamine,” Archivum Immunologiae et Therapie Experimentalis, 24(6): 851-852 (1976).
Abou-Gharbia et al., “Psychotropic Agents: Synthesis and Antipysychotic Activity of Substituted B-Carbolines,” J. Med. Chem., 30(6):1100-1115 (1987).
Ahsan et al., “Reserpine Anlogues: Synthesis of B-Carboline Derivatives,” J. Chem. Soc., pp. 3928-3920 (1963).
Database CA on STN, AN 7:66733, Rosenmund et al., “Chemistry of indole II . . . ,”Chem Ber.103(2): 496-509 (1970).
Database CAOLD on STN, AN CA51:10524d, Hellman et al., “N-Mannich bases (VI) condensation . . . ,”Direct Submission(1953).
Database CAPLUS on STN, An 1977:439214, Misztal et al., “Synthesis and pharmacologic properties of pyridoyl . . . ,”Arch Immuno Ther Exp.24(6): 851-862 (1976).
Pachter et al., “The Chemistry of Hortiamine and 6-Methoxyhetsinine,” J. Amer. Chem., 83:635-642 (1961).
Rehse et al., “Dopaminanaloge 1,2,3,4-Tetrahydro-B-Carboline,” Arch. Pharm., 311(1):11-18 (1978).
Shoji et al., “Two Novel Alkaloids from Evodia Rutaecarpa,” J. Natural Products, 52(5):1160-1162 (1989).
Himmer et al., “Synthesis and Antibacterial in Vitro Activity of Novel Analogues of Nematophin,” Bioorganic & Medicinal Chemistry Letters, 8(15): 2045-2050 (Aug. 1998).
Jianxiong et al., “Synthesis and Antistaphylococcal Activity of Nematophin and Its Analogs,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, 7(10): 1349-1352, (May 20, 1977) XP004136332.
Hungarian Search Report dated Dec. 31, 2003.
U.S. Appl. No. 10/407,028, Methods of Agonizing and Antagonizing Fab K, filed Apr. 4, 2003, Pending.
U.S. Appl. No. 10/292,687, Fab I Inhibitors, filed Nov. 12, 2002, Pending.
U.S. Appl. No. 10/339,092, Disubstituted Imidazoles Useful in the Treatment of Bacterial Compounds, filed Ja. 9, 2003, Pending.
U.S. Appl. No. 10/429,923, Antibacterial Compounds, filed May 5, 2003, Pending.
U.S. Appl. No. 10/089,739, Fab I Inhibitors, filed Oct. 6, 2000, Pending.
U.S. Appl. No. 10/089,740, Fab I Inhibitors, filed Oct. 6, 2000, Allowed.
Miller et al,: Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FabI); J. Med. Chem. 2002, vol. 45, pp. 3246-3256.
DATABASE Crossfire Beilstein, 1966, Database accession No. 2819049, 2819050 XP002216033.
Database CAPLUS on STN, AN 1986:68547, Stuetz, et al., “Synthesis and Structure Activity . . . ,”J Med Chem. 29(1): 112-25, (1986).
Database CAPLUS on STN, AN 1991:428908, Fuse, et al., “Preparation of cinnamamide derivatives . . . ,”EP407200A1. (1991).
Database CAPLUS on STN, AN 1999;325910 Aslanian, et al., “Preparation of phenylalkylimidazoles . . . ,” WO99/24406. (1999).
DeWolf, Jr. Walter E.
Jakas Dalia R.
Miller William H.
Newlander Kenneth A.
Seefeld Mark A.
Affinium Pharmaceuticals, Inc.
Foley & Hoag LLP
Huang Evelyn Mei
LandOfFree
Fab I inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fab I inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fab I inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380177